Ira Weisberg Email & Phone Number

Woodland Hills, Ca, Us

Amherst Pharmaceuticals has acquired the Zolpimist Oral Spray assets and, in a partnership with MAGNA Pharmaceuticals, is getting ready to launch Zolpimist in Q1, 2016. Zolpimist is the first and only FDA approved oral spray version of zolpidem (Ambien).

Weisberg Consulting provides services in Business and Corporate Development, Strategic Marketing and Operations. Strong knowledge and experience in complex deal structures, funding, sales and distribution channels, compliance, regulatory, reimbursement systems and public relations. Provides expertise in corporate funding, licensing and other growth centric deal structures

Research Triangle Park, Nc, Us

CEO (Acting) and a member of the Board of Directors of AlphaVax, a development stage company developing a novel vaccine technology with broad applications against infectious disease, cancer and biodefense threats.

Dk

Business and Corporate Development• Developed and executed strategies for the development of a US and global commercial business focused on solid organ transplantation, immunosuppression and cardiovascular therapeutics• Initiated and closed on a $105 million transaction with Cowen Healthcare Royalty in which we monetized the royalty stream of a key product• Negotiated several off-shore licensing deals on several key products in areas such as Europe, Korea, Middle East, Africa and South America.• Initiated and closed on a partnering arrangement to enhance product development and add new products into the development portfolioSales and Marketing• Directed the development of a launch and marketing strategy for the company's lead product• Developed a Managed Care Advisory Board• Developed and executed a pharmacoeconomic clinical evaluation strategy

• Developed and executed strategies for the development of a US commercial enterprise focused on oncology, metabolic syndrome and cardiovascular disease risk reduction• Developed a global licensing strategy for Chugai as well as annualBusiness Development plans and objectives• Developed an acquisition strategy for an oncology and cardiovascular acquisition• Led negotiations on the acquisition of a cardiovascular opportunity with a deal value of more than $500 million• Developed and implemented an opportunity review/assessment process along with a financial modeling and analysis tool for opportunity evaluation• Developed a portfolio management evaluation program for Chugai

Business and Corporate Development•Led the development of a global business valued in excess of $750 million•Negotiated a Licensing Agreement with the global medical device company•Negotiated a Supply and Distribution Agreement that resulted in a net savings of $100 million over several years•Led the successful divestiture of a division to LabCorps •Developed global strategic business plans for the Wound Healing and Critical Care Business Units •Developed a cross-functional opportunity evaluation team of key stakeholders to qualify and evaluate opportunities•Developed and implemented quantitative opportunity evaluation methods •Negotiated a co-marketing arrangement with a Japanese company for an immunosupportive oncology product•Negotiated a licensing and development agreement with a pulmonary delivery device firm - deal value of $350 million•Negotiated a licensing and development agreement for a specialty medical product valued at $500 million•Developed an Alliance Management program•Managed deals related to the development of late-stage products to fill gaps in the R&D pipeline in a number of therapeutic areas such as Immunology, Oncology, Critical Care Medicine, Cardiovascular Disease and Wound HealingSales and Marketing•Directed sales, strategy and marketing for the Critical Care and Oncology product line to hospitals, acute and non-acute treatment centers and physician offices•Managed a sales staff of 40 representatives as well a leading all marketing functions•Developed and executed a life cycle management strategy for Critical Care products•Responsible for the launch and sales management a thrombolytic for the treatment of acute myocardial infarctions. •Developed and executed a Channel Partner Development program to enhance mind share within these key channel groups and build brand loyalty•Increased sales of the Critical Care and Oncology products by more than 8%•Developed and executed an internet and e-business program